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Exploratory evaluation of variation in statin take up amongst high risk patients in 
Nottingham City 
 
Introduction 
The NHS Health Checks programme is a national policy for England delivered in primary care, that aims to 
invite all 40-74 year olds, without a prior diagnosis of cardiovascular disease (CVD), diabetes, chronic kidney 
disease or hypertension, for a risk assessment and treatment (if necessary) once every five years (DH 
Vascular Programme 2008; NHS Health Check Programme 2009)⁠. The Health Checks programme is 
designed, through this risk assessment and preventive treatment, to reduce the incidence of CVD as well as 
help to tackle health inequalities and the rise in obesity (DH Vascular Programme 2008)⁠. For primary 
prevention the programme, following NICE guidance, recommends that patients found to be at high CVD risk 
(those estimated to have a 10-year risk of 20% or greater, as measured by QRisk2) should be offered 
interventions including statin medication and lifestyle changes, to reduce modifiable risk factors (National 
Institute for Health and Clinical Excellence 2010)⁠.  
 
Practices within Nottingham City CCG conduct targeted CVD screening, and are rolling out the Health 
Checks to all 40-74 year olds. From 2009-11, 10001 eligible patients were screened. Of these, 4260 patients 
have been found to be high risk, but only 2541 are known to have been started on statin medication (see 
Figure 1.1) [REF public health audit within Nottingham City CCG]. The reason for this disparity is not 
understood, and there is known to be wide variation, within and between practices, in statin uptake in high 
risk patients [REF - PCT Board Paper 198/11].  
 
This small (qualitative) pilot study aims to explore the variation in statin uptake among GP practices within 
NHS Nottingham City CCG by focusing on the reasons why those who have been identified as high risk (and 
thus are suitable to take a statin) accept or decline statin medication.  
 
 Figure 1.1 
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Background 
Previous studies of statin prescribing have often focused on the health inequalities associated with variation 
in statin uptake in the general (as opposed to a high risk) population. Studies have explored the contribution 
of variables such as social deprivation and CVD risk factors (age, gender, ethnicity, etc) to levels of uptake. 
(Thomsen et al. 2005; Ward et al. 2007; Ashworth et al. 2007; Packham et al. 1999; Packham et al. 2000)⁠; 
indeed two such studies were conducted in Nottingham, between 1996 and 1998, showing increased statin 
use overall and lower correlation between deprivation scores and statin use over time (Packham et al. 1999; 
Packham et al. 2000)⁠. In general results are idiosyncratic and regression models typically explain only 
between 15-35% of the variation in uptake. Furthermore, studies at the practice or population level should be 
interpreted cautiously, since it may be difficult to discriminate variation in uptake due to social differences in 
health, the quality of healthcare or the use of healthcare. Clearly however, health inequalities in the general 
population threaten the success of policies such as the Health Check, if, to take one example, those with a 
higher disease burden are systematically less likely to attend for the Health Check.  
 
More relevantly, the Health Check programme itself has been the subject of study, with authors modelling the 
prevalence of CVD risk factors in the target population (Dalton, Soljak, et al. 2011), and investigating 
variation in risk factor recording (Artac et al. 2012)⁠ as well as investigating variation between (what were 
formerly) Primary Care Trusts (PCTs) in the ways that the programme is implemented (C. E. M. Graley et al. 
2011)⁠. Notably, (Dalton, Bottle, et al. 2011)⁠ studied the uptake of the Heath Checks programme within 
Ealing PCT between 2008-09, finding a lower than expected uptake. Perhaps most relevantly (Dalton, Bottle, 
et al. 2011)⁠ found low overall statin prescribing among high risk patients (45%, actually slightly higher than 
the Nottingham data), which they speculated may be due to: a proportion of high risk patients with no history 
of vascular management declining statin medication; patient and practitioner beliefs about the risks and 
benefits of statin medication as well as beliefs about the idea of treating risk; and additionally, due to a 
measurement bias introduced by long delays between attending for Health Check and being prescribed a 
statin (2011: 427).  
 
Below the population level, studies have examined the sociological factors which affect statin prescription. 
Importantly, (Mohammed et al. 2012)⁠, in a study of primary prevention in the West Midlands in the UK, 
found that high risk patients are often not prescribed a statin despite their eligibility; although more risk 
factors were found to increase the likelihood of statin prescription. Similar studies in the UK have also 
examined how patient values are integrated into treatment decisions concerning CVD risk (Montgomery et al. 
2001; Bryan et al. 2006; Lewis et al. 2003). The idea that patient choice must involve genuine collaboration 
between doctor and patient in order to integrate values and preferences with evidence is underscored by a 
number of authors. For example, (Bryan et al. 2006)⁠ found that patient preferences are “largely over-ridden 
in the clinical consultation”, and (Lewis et al. 2003)⁠ found much diversity in the ways that patient's assess 
the level of benefit that is considered worthwhile when balanced against the length of treatment (e.g. 5 or 10 
years), potential side effects, the inconvenience pill taking and the availability of other ways of managing risk 
through lifestyle changes; noting the challenges this poses when set against guideline recommendations.  
Methods 
 
Study Design and Sample 
Study Design: 
This was a small-scale qualitative study exploring reasons for variation in take up of statin prescriptions 
among patients identified as being at high risk. From 6 practices within Nottingham City CCG, short (10 
minute) telephone interviews were conducted with a total of 28 patients, and longer (30 minutes) face-to-face 
interviews were conducted with 4 GPs. 
 
Practice Sample: 
Practice level data was obtained from Nottingham City CCG. Statin uptake (the percentage of high risk 
patients identified by a practice, who subsequently took up a prescription of a statin) ranged from 0% to 
87.5% (median 31.8%). From the list of 61 practices in the CCG, a stratified sample of 14 was randomly 
taken, according to low (4 practices), medium (6 practices) or high (4 practices) levels of statin uptake (9 of 
the 61 practices that identified less that 6 high risk patients were excluded). Of these 14 practices, 6 agreed 
to participate in the study. Uptake in these 6 practices ranged from 11% to 64% (median 30%) – See Table 
1.1  
 
TABLE 1.1 Practice Sample 
 
 
 
 
 
 
 
 
 
 
Patient Sample: 
Letters were sent to a total of 160 high risk patients at the 6 participating practices, inviting them to take part 
in a short telephone interview. 28 patients responded and completed the interview (a further 5 patients 
responded but did not complete the interview). The sample of patients interviewed was self-selecting, and 
was composed of generally older (93% 60 or over; 56% 70 or over) male (71%) patients, the majority of 
which were taking statin medication (57%) and unanimously described their ethnicity as white (100%) – See 
Table 1.2 
 
 
 
Practice Responders Responders on Statin Total on Statin
n % n % %
A 6 3 50 15 3 20 40
B 5 1 20 33 10 30 15
C 15 11 73 51 19 37 29
D 2 1 50 25 16 64 8
E 0 27 8 30 0
F 0 9 1 11 0
Total 28 16 57 160 57 36 18
Total High 
Risk
Survey 
Response 
Rate
TABLE 1.2 Patient Sample 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
GP Sample: 
GPs at the 6 participating practices were also invited to be interviewed. 4 GPs, across 3 practices (practices 
A, B and C), were interviewed: the two GPs at the same practice were interviewed together.  
 
Data Collection 
Patients: 
Telephone interviews with patients were not recorded, but notes we taken during and immediately after each 
interview. Basic demographic information for patients was recorded (Sex, Age, Ethnicity) as well as whether 
they were currently taking any cholesterol-lowering medication. All further questions in the telephone 
interview were open-ended. They broadly covered: satisfaction with GP; GP's communication generally, and 
specifically in the case of the Health Check; and Patient's attitudes to statin medication, including reasons for 
accepting or declining a prescription, knowledge or experience of side effects, and knowledge or concern 
about managing cholesterol level. 
 
GPs: 
Interviews with GPs were recorded from which a transcript and summary notes were written. GPs were 
interviewed after the majority of patients had been interviewed and questions were formed in response to 
preliminary analysis of the patient data. Again questions were open-ended. GPs were asked broadly about: 
their aims for the consultation; how they explain CVD risk to patients, and the trade-off between lower-risk 
and possible side effects; how they explain the relationship between statin medication and lifestyle changes; 
and how they integrate patients' values with evidence.  
 
 
Responders
n %
Sex Female 8 29
Male 20 71
Age Group 40-49 0 0
50-59 2 7
60-69 10 37
>70 16 56
Ethnicity White 28 100
Taking Statin Yes 16 59
No 12 41
Data Analysis 
Data from the interviews with patients and GPs was analysed thematically. The thematic categorisation of the 
data was not conducted on the basis on any stronger theoretical commitments than were necessary for 
generating the intuitively-salient interview questions. In that sense, the analysis proceeded 'inductively'. 
Furthermore the themes used to categorise the patient data were not exported, a priori, onto the GP data, or 
vice versa. Although clearly there is, as one would expect, much overlap. 
 
Results 
 
Patients: 
Lifestyle modification 
Almost all patients interviewed had discussed their diet and level of exercise, regardless of whether they 
accepted statin medication. Though whether the discussion took place with either or both the nurse or the 
GP, and whether the patient received written and, or, verbal information was variable – in the typical case, 
patients discussed their lifestyle with both nurse and GP, and also received written information from the 
nurse. Overall, as a result of meeting with both the nurse and GP, the majority of patients received both 
written and verbal advice about diet and exercise. Levels of concern about cholesterol level and heart health 
was also even between those who accepted statin medication and those who did not. Patients were also 
asked about concordance using a four question scale from Morisky et al (1986) and patients came out as 
`medium adherence’. 
 
There was a consistent view among the patients interviewed that modification of lifestyle factors was a 
preferable way to manage their cholesterol and heart health, and indeed some patients believed these were 
the most important factors. In this respect there was a difference between those patients taking statin 
medication and those not: those not taking a statin spoke about lifestyle modification in terms of a 
“challenge” or “vow” and something they wanted to do for, or “prove to”, themselves. In contrast, of those 
patients who were taking a statin and believed that lifestyle modification was an important part of managing 
their cholesterol many held the view that their diet and level of exercise was already adequate; despite many 
also noting their occasional 'naughtiness' in relation to diet.  
 
There was also a temporal difference between some of those patients taking and not taking a statin. Patients 
not on a statin sometimes reported that they had decided with their GP to try lifestyle modification first, which 
would then later be re-assessed. Some patients who were taking a statin reported being at a later stage of 
this same process, that is, having tried lifestyle modification and then subsequently accepted statin 
medication (this is noted in the limitations section below). 
 
Views about medication 
Almost all patients not taking a statin expressed a preference to avoid medication if possible. Notably, many 
of those patients also thought they would be happy to take medication if it was necessary; but believed as a 
result of discussion with their GP, that is was not (or not yet) necessary. Most patients who were taking a 
statin had the opposite view and reported they were happy taking medication. They cited a number of 
reasons why, such as “lowering risk” or avoiding a heart attack, as well as believing that it was necessary 
(sometimes despite the fact they would prefer not to take medication, or because they were previously 
unsuccessful with lifestyle modifications).  
 
 
Side-effects 
Patients not taking a statin had relatively little to say about the side effects of statins, and their general level 
of concern about side-effects was low. Only two patients cited possible side-effects as the reason why they 
declined statin medication. Overall, equal numbers of patients thought that potential side-effects were well or 
poorly explained to them. Similarly there was a roughly even split between good and poor explanations of 
side-effects among those patients who had accepted statin medication. And again, the general level of 
concern was low; even among those who had experienced side-effects themselves. Across all patients, 
whether taking a statin or not, information about side-effects came from the same range of sources: the 
experience of friends and family, pharmacists and the leaflets that come with the medication, as well as what 
was given to them by the nurse at the initial screening, or later by the GP.  
 
Trust and Choice 
The majority of patients who were not taking statin medication stated this was because they had decided in 
conjunction with their GP to try lifestyle modification first. They frequently made reference to the fact that the 
GP was very supportive of their preference for making lifestyle changes, and that they felt well monitored and 
well looked after by their GP. Only one patient complained of their GP's “statin or goodbye” attitude. In 
contrast to this, patients taking statin medication cited their trust in their GP's advice as the primary reason 
for accepting it. Many patients expressed the view that they “trust utterly” their GP, or that one must “go 
along” and “not argue” with the GP. Again patients reported that they felt well monitored, but this was instead 
related back to the idea that the GP 'knows best', rather than supports their preferences.   
 
GPs: 
Aims 
All the GPs interviewed shared the straightforward aim for their consultations with high risk patients, which 
was to: “modify all of the modifiable risk factors, if I can, for the benefit of the patient” (GP3), depending on 
the patients' risk factors. All the GPs emphasised that they aim to explain and get the patient to understand 
the benefits and risks of statin medication; reiterating the discussion the patient would have had previously 
with the nurse. Other things equal, one GP explicitly stated that their aim is: “[to] get people with cholesterol 
onto a statin, because I think that's one of the best ways of approaching it” (GP3). 
 
Discussion of both lifestyle modification and statin treatment was said to be a feature of patients' interactions 
with both the nurse initially and GP later. While the division of labour between nurse and GP, in terms of who 
gave different kinds of advice, differed according to the GPs interviewed, in general the GPs stated that they 
try to reiterate much of the discussion that had been started by the nurse. All GPs held the view that their 
discussion with the patient should cover the full range of treatment options. For example: “you wouldn't just 
give somebody a medication without advising them... [you] wouldn't give someone a statin without the 
associated lifestyle advice, you would also say you can help yourself to by doing x, y, z” (GP1). However one 
GP noted that they try to focus more heavily on the “the prescribing and pharmacological side” of treatment, 
leaving lifestyle advice mostly to the nurse, so that “lifestyle advice [is] given as a baseline... [to be] built 
upon later on” (GP4). Indeed some GPs reported that additional written information about statins was 
sometimes given to patients, the content of which went beyond the nurses “shiny leaflets”.  
 
Barriers to uptake and concordance 
GPs referred to a number of reasons why patients might be reluctant to accept (or continue) statin 
medication. All GP's noted that they see patients who are sceptical about the need for a statin, or concerned 
about taking a statin.  
 
The foremost reason given by GPs was patients' worries of side-effects, often based on the experiences of 
friends or family and also often exaggerated. More generally GPs felt that patients' concerns were often 
based on misinformation: two GPs singled out the Daily Mail in particular as a source of misinformation about 
statins. One GP noted that dealing with these misunderstandings often gets in the way of the discussion they 
want to have with the patient: “it's quite a pain to be going through that, at times” (GP4). Also food labelling 
was noted as an issue, when products such as Benecol over-promise their benefits and can give patients the 
wrong idea. Similarly, apparently contradictory advice given by a patient's previous GP was noted as 
something that needed further discussion, for example, around the need to explain that the patient was now 
older, which itself increased their risk. 
 
Poor concordance was also partly blamed on experience of side-effects, or the slightly greater inconvenience 
of night-time dosing. However GPs put much more emphasis on concordance problems resulting from poor 
explanations of statin treatment, particularly the reasons why patients were taking it and what to expect in 
advance. For example, explanation of the fact that the patient may not feel ill because it is their risk that is 
being treated was seen a key part of maintaining concordance. Also, the GPs felt clearly that if the possible 
side effects are not explained in advance, then patients may have problems and give up without contacting 
them. All GPs stated that patients' attitudes towards medication and concordance crucially depended on the 
quality of the discussion they had with their GP.  
 
GPs expressed a mixed attitude towards the efficacy of lifestyle changes. While the GPs thought that lifestyle 
changes have a “definite role” (GP4) to play in managing risk and that patients may be able to lower their risk 
without needing medication, most thought that lifestyle changes were difficult to sustain. One GP explicitly 
stated that leaving high risk patients to just make lifestyle changes made them “uncomfortable” (GP4), and 
other GPs talked judging whether a patient was able to make the required changes. For example,  one GP 
stated:  “[you consider how] realistically they [the patient] would be able to achieve the changes in their diet 
and lifestyle” (GP2). The effect size of lifestyle changes was also questioned: “in terms of exercise and diet 
changes... you're thinking to yourself, your [the patient's] total cholesterol is 6.5, it's going to come down to 
5.5 in an optimistic scenario” and later: “can it [lifestyle changes] completely reverse it [being at high risk] – 
no” (GP4). More specifically, the efficacy of diet changes was questioned by one of the GPs: “[I am] pretty 
sceptical about diet having any effect”, however “exercise and weight loss, those are things I will push most” 
(GP3). Furthermore, in relation to exercise, the level of activity patients engage in was also highlighted; 
simply walking regularly was not viewed as being sufficient, although patients may think it is. 
 
Facilitating uptake and concordance 
All GPs expressed a consistent view about how to facilitate uptake and concordance with statin medication. 
 
Properly explaining the benefits and risks of treatment to the patient was unanimously thought to be the a 
key part establishing trust and thereby facilitating uptake and maintaining concordance: “If you've had a good 
quality discussion with them at the beginning and they know what to expect then they're much more likely 
again to trust what you're saying” (GP1). GPs thought an explanation of risk, which helped the patent to 
understand what is meant and achieved by modifying risk factors enabled patients to choose the best 
treatment option. For example: “[good explanation] helps them [that patient] place the question of cholesterol 
medication in their own framework of values” (GP3). 
 
All the GPs mentioned particular strategies for explaining the benefits and risks to patients, in a way that 
facilitated uptake and concordance. Most simply, the GPs noted that concerned or sceptical patients are 
given different kinds of explanation: “I would tailor the discussion to the patient depending on whether they 
had told me or whether I suspected that they were a bit sceptical about taking medication” (GP1). For 
example, placing particular emphasis on the idea that it was overall risk that was being targeted. Hence, GPs 
noted that they spent time explaining to patients that they may not feel ill now, or have particularly high 
cholesterol, but never the less – because risk was calculate from multiple factors – could still be high risk. 
Similarly GPs stated that the potential side-effects of statin treatment were introduced in the discussion even 
with unconcerned patients, on the basis that making patients aware of what they might experience and the 
ways that it could be dealt with by the GP, made them more likely they to work with the GP to continue 
treatment if they experienced side effects.  
 
More concretely, GPs explained that they discussed risk with patients by using specific examples such as 
imagining '10 people in a room' or '5 people just like you', or as one GP expressed it, using a boiler 
metaphor: “you don't let your boiler get sludge in there” and by servicing it “you're not curing it, you're 
preventing it”, emphasising that “the boiler is going to breakdown, if you don't do anything about it” (GP4). It 
was also stated that explanations referring to the number-needed-to-treat, rather than percentages were 
more likely to aid patients' understanding. The use of diagrams or decision-aids was further noted as being 
useful because they: “[help patients see the importance of] why we make a fuss about it [cholesterol level], 
and why we want to include them in the green bunch [referring to the smiley faces on the decision aid]” 
(GP3). Although one GP noted that the decision-aids could sometimes backfire because “if you're talking 
about 30% risk or 25% risk there are more smilies regardless” and because “[patients say] these patients 
would remain smiley anyway, whether they take the tablet or not” (GP4). 
 
All GPs emphasised that in addition to providing a good explanation of treatment options (which in itself was 
claimed to facilitate uptake and concordance) the process of negotiation and shared decision-making with 
patients was also key. For example: “I think including people and making it an open discussion rather than a 
prescriptive 'I think you should, need, to take this otherwise you'll die of a heart attack'... means that nearly 
everyone I personally start on statin still takes it, as long as there is no reason for them not to” (GP3). 
Including patients in a negotiation about their treatment was linked to a number of other ideas. For example 
one GP linked it to increasing trust: “They [patients] trust what you're saying if you've negotiated with them” 
(GP1), while another put the negotiation in terms of ownership: “you don't want a confrontation, you want 
someone to work along... [so] it's his [the patient's] ownership, not my agenda... if it is me, they'll never do it 
[lower their risk]: make them own it and then they push you to do something about it” (GP4). The same idea 
was put in terms of responsibility as well, where the negotiation process is used to highlight that it is “as 
much their responsibility as ours [to manage their risk].” and that “it is not just up to me to fix your Qrisk” 
(GP2). In relation to concordance, the GPs thought that negotiating with patients would encourage them to 
monitor things themselves, come back to the GP with any problems, and want to do what they can to help 
themselves.  
 
One important strategy in the negotiation with patients about their treatment, especially the concerned or 
sceptical patients, was an initial attempt at lifestyle modification before starting medication. For example, one 
GP states that “most people would have that period of trying lifestyle, unless they had a major risk factor” 
(GP2), the advice from another GP being that patients would: “try it [lifestyle changes] for three months time, 
[or] six months time, [then] we'll recheck it [risk]” (GP4). Indeed, to demonstrate this negotiation with patients, 
one GP talked about certain 'catchphrases' they used such as: “The last thing we want to do is to lumber you 
with medication when you don't need it” and “I want to give you the opportunity to modify this in other ways, 
before we resort to that [medication]” (GP1). The purpose being to give patients the opportunity to try their 
preferred treatment options first; which again was cited as being important for maintaining concordance later 
on, as one GP claimed: “yes you give in when they want to try lifestyle, but then they own the problem and 
they come back to you wanting to do something else” (GP4) 
 
A further negotiation strategy used by GPs concerned patients experiencing side-effects from statin 
medication. GPs reported that in some cases they “negotiate a break” (GP1) or “drop a dose” (GP2) of a 
patient's medication, as a means to test whether problems are statin related. Negotiating these breaks or 
reductions for a set period of time was used to keep the patients 'on track'. GPs stated that patients stopped 
taking medication themselves because of problems, and so by the GP initiating a break or reduction, the 
patient could be monitored and treatment re-adjusted later. For example, one GP emphasised “working along 
with them [patients experiencing side-effects], in terms of, if they want to reduce the dose to try it first, but 
then you have to go back at it and bring it back up again in three months time, six months time, and ask 
them 'what's happened, how are you getting along?'” (GP4). 
 
The negotiation with patients was seen as the best way for GPs to use their expertise to integrate the 
patients' values into the treatment decision. GPs noted that in addition to the concerned or sceptical patients, 
for some patients, the choice to accept statin medication could be their first long term medication, and so 
being sensitive to those concerns was important. The importance of patients' values was further underlined 
by one GP's claim that by recommending medication or lifestyle changes “we may be having an impact on 
the quality of life [of the patient] in ways we hadn't intended”, and who therefore stated that they avoided 
being paternalistic about treatment options. Indeed even though some patients' values may seem 
'unreasonable' or a poor justification for avoiding statins one GP noted that “if that's what he [the patient] 
values above being a green smiley face, that's his decision” (GP3). Other GPs gave examples of 
hypothetical patients, for whom they would alter the explanation of treatment options in response to their 
values. For example, one GP talked about a patient who “absolutely detest[s] taking tablets... you may say to 
that person, well you're a smoker and actually if you modify that then you can reduce your risk quite 
considerably” (GP1).  
 
When to prescribe 
The GPs presented more mixed views on whether patients on the borderline of being high risk should be 
advised or treated differently. In some cases borderline patients were thought of as giving a GP more 
flexibility with treatment options. For example, one of the GPs interviewed stated that their approach to 
borderline patients “depends on what you have to play with [in terms of risk factors]” (GP2). Similarly in 
relation to the NICE guidelines (National Institute for Health and Clinical Excellence 2010)⁠ another GP 
noted that “I treat guidelines as exactly that, as a guide... there are no clear rules” and later said that “if it 
[Qrisk] is just above or below 20, then there's no magic cut off” (GP1). In contrast other GPs expressed the 
view that patients with a Qrisk between 15-20% ought to be thinking about their heart heath and statins; 
indeed, one GP stated that all borderline patients, between 15-25% “should be on a statin” (GP4).  
 
In relation to this, the GPs also highlighted the shift from absolute numbers, such as cholesterol level, to risk 
measures. Saying for example that “these days we don't treat the numbers in the same way that we used to” 
and that “it's not just if you're cholesterol is high you're offered a tablet” (GP1). Equally however, another of 
the GPs also stated that they still like to invite back patients found to have high cholesterol, even if their Qrisk 
is below 20%, so that the discussion about heart health can begin.  
 
The GPs were consistent in their views about higher risk patients, and all stated that they recommend statin 
medication more strongly with those patients. For example if the Qrisk was over 25% it was thought that “it is 
a given that you're [the patient] going to have a statin” (GP2), and other GPs talked in terms of a “need to be 
realistic with them [the patient]” (GP1), or challenging patients' preferences by asking “do you really not want 
to take this?” (GP4). 
 
  
Discussion 
Summary of Main Findings 
 
 Patient uptake was associated with trusting and accepting GP's advice. There was less uptake 
among patients who reported greater shared-decision making with their GP. 
 
 Few patients expressed serious concern about the possible side-effects of statin medication. 
 
 Some patients felt strongly about trying lifestyle modification in the first instance; seeing this as a 
personal challenge.  
 
 GP's believed that non-paternalistic and shared decision-making approaches were crucial to 
facilitating uptake and ensuring subsequent concordance with statin medication. Key aspects of this 
were: 
 A good explanation of risk, and why patients therefore need a statin. 
 Pre-emptive explanation of possible side-effects and how they can be dealt with. 
 Negotiation of treatment options with the patient, in order to encourage trust, ownership and 
responsibility. In particular (1) integration of patient values, even if they may not seem 
'reasonable', (2) period of trying lifestyle modification prior to starting statin medication, (3) 
breaks or reductions in statin medication following experience of side-effects. 
 
The results from this small qualitative study suggest a tension between the dual aims of increasing patient 
choice and increasing uptake of statin medication. The results from the GP interviews demonstrate that 
negotiation with the patient about treatment decisions is crucial for uptake and concordance; though this 
appears to carry with it greater variation in uptake as patients try alternatives to statin medication in the first 
instance. Conversely, the failure of concordance or uptake that GP's thought was most significant, was due 
to poor explanations of statin treatment and lack of shared decision-making. The results from patient 
interviews suggests this does happen but, encouragingly, is not typical. These results however require 
verification in larger more representative samples. 
 
Implications for Practice 
From one email response: “Implications are that a) the choice agenda is likely to increase clinical variation b) 
where this is the case clinical variations shouldn't necessarily be regarded as `unwarranted' - though as the 
CCG is also measured against `outcomes'  there should probably be a follow up on those patients who 
choose lifestyle change. “ 
 
Limitations 
The sample of patients was self selecting and clearly skewed towards older, white males. The sample is not 
representative of the practices' populations. This is problematic because the patients in the sample who  
were taking a statin reported that they did so mostly because they always trust and followed their GP's 
advice. This is known to be a characteristic of older patients (Vick & Scott 1998)⁠, however younger patients  
- under represented in the sample - may accept statins for different reasons. Response rates for this study 
were low and difficult to engineer to be more representative. Future research may wish to employ other 
survey methods, for example, questionnaires which, while less rich in qualitative terms, may lower the barrier 
to participation and thereby encourage a larger response from patients. This would also serve as a useful 
corroboration of the results by a different kind of evidence, if results were consistent.  
 
It became apparent during the study that following the Health Check consultation with the GP there may be a 
period of time where the patient tries lifestyle modification before statin medication. The patients interviewed 
did not all have their Heath Check at the same point in time, nor was the date of the Health Check recorded 
as part of the study. Consequently the association of lower uptake and greater shared-decision making could 
be a result of those patients not on statin medication being interviewed 'too early'. More generally, there may 
be systematic differences in patient responses, depending on how recently they had their Health Check. This 
was not controlled for in the present study. Future research should record the date of Health Check in each 
case and check findings for temporal correlations.  
 
This is also related to a second concern. Patient preferences, for example for lifestyle modification as 
opposed to statin medication, were all self-reported. The primary reason this is a concern in the present 
study is that there is no way to discriminate whether treatment decisions reflect patient's stated preferences 
or whether the patient's stated preferences follow the treatment decision. For example, most patients 
interviewed expressed a preference to avoid medication unless it was necessary, but it is not clear whether 
there judgement about whether it is necessarily is a consequence or a cause of whether they are receiving 
statin treatment. Future research could investigate this through follow-up and 'tracking' of patients, and by 
being more closely tied to the timeline (consulting nurse, consulting GP, initial treatment, 3 or 6 month follow-
up) which patient's follow. 
 
GP's views on their practice were also self-reported. Through interviewing patients as well, the present study 
included some further validation of whether the GP accounts of how they interact with high risk patients 
reliably reflected that interaction. However, the present study is less robust in comparison to other more 
observational ethnographic methods. Future research could explore the doctor-patient interaction more 
directly through these methods.  
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